Skip to main content
Erschienen in: BMC Nephrology 1/2017

Open Access 01.12.2017 | Correction

Correction to: Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study

verfasst von: Sandra Wagner, Marie Metzger, Martin Flamant, Pascal Houillier, Jean-Philippe Haymann, François Vrtovsnik, Eric Thervet, Jean-Jacques Boffa, Ziad A. Massy, Bénédicte Stengel, Patrick Rossignol, for the NephroTest Study group

Erschienen in: BMC Nephrology | Ausgabe 1/2017

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The online version of the original article can be found under doi http://​dx.​doi.​org/​10.​1186/​s12882-017-0710-7
In the original version of this article [1], published on 12 September 2017, the explanation of a and b in the footnote of Table 2 were switched during typesetting. In this Correction Table 2, the incorrect and correct version of its footnote are shown. The affected part of the footnote is marked in italics. The original publication of this article has been corrected.
Table 2
Odds ratios of low or high plasma potassium associated with baseline patient characteristics – Multinomial logistic regression using patients with plasma potassium of 4–5 mmol/L as the reference group
  
Plasma potassium (mmol/L)
<4
>5
Age (per year)
 
0.99 (0.98–1.00)
0.98 (0.96–0.99)
Women vs men
 
1.49 (1.16–1.90)
0.47 (0.30–0.72)
Sub-Saharan vs other ethnicity
1.35 (0.99–1.83)
1.15 (0.66–1.99)
mGFR (ml/min/1.73m2)
 
<15
0.11 (0.05–0.23)
29.65 (10.87–80.88)
 
15–30
0.26 (0.18–0.38)
13.58 (5.71–32.3)
 
30–45
0.47 (0.34–0.63)
5.70 (2.42–13.45)
 
45–60
0.67 (0.49–0.90)
2.70 (1.07–6.85)
 
>60
1
1
BMI
 
<19
1.46 (0.83–2.59)
1.49 (0.65–3.43)
 
19–25
1
1
 
25–30
0.85 (0.66–1.10)
0.78 (0.51–1.20)
 
>30
0.78 (0.57–1.07)
1.05 (0.65–1.73)
Smoking status
 
Never smoked
1
1
 
Former smoker
0.85 (0.66–1.11)
1.02 (0.67–1.54)
 
Active smoker
0.76 (0.54–1.06)
1.66 (1.03–2.67)
Mean blood pressure (per mmHg)
1.01 (1.00–1.02)
1.01 (0.99–1.02)
Cardio-vascular history
0.63 (0.46–0.88)
0.81 (0.51–1.28)
ACR (mg/mmol)
 
<3
1
1
 
3–30
1.07 (0.82–1.40)
1.25 (0.76–2.08)
 
>30
0.80 (0.59–1.10)
1.13 (0.67–1.90)
Diabetes
 
0.86 (0.66–1.13)
1.56 (1.04–2.34)
Urine potassium
0.99 (0.99–1.00)
1.01 (1.00–1.01)
Serum albumin
 
≥35
1
1
 
<35
1.23 (0.87–1.74)
1.23 (0.76–1.98)
Serum potassium increasing drugsa
 
0.58 (0.44–0.78)
2.50 (1.17–5.35)
Serum potassium-lowering drugsb
1.70 (1.33–2.17)
1.01 (0.69–1.49)
a loop or thiazide diuretic, kayexalate or bicarbonates b ACEi or ARBs or potassium-sparing diuretics
BMI body mass index, CVD cardiovascular disease, mGFR measured GFR, ACR, ratio of urinary albumin to creatinine
The analyses was adjusted for center
Table 2
Odds ratios of low or high plasma potassium associated with baseline patient characteristics – Multinomial logistic regression using patients with plasma potassium of 4–5 mmol/L as the reference group
  
Plasma potassium (mmol/L)
<4
>5
Age (per year)
 
0.99 (0.98–1.00)
0.98 (0.96–0.99)
Women vs men
 
1.49 (1.16–1.90)
0.47 (0.30–0.72)
Sub-Saharan vs other ethnicity
1.35 (0.99–1.83)
1.15 (0.66–1.99)
mGFR (ml/min/1.73m2)
 
<15
0.11 (0.05–0.23)
29.65 (10.87–80.88)
 
15–30
0.26 (0.18–0.38)
13.58 (5.71–32.3)
 
30–45
0.47 (0.34–0.63)
5.70 (2.42–13.45)
 
45–60
0.67 (0.49–0.90)
2.70 (1.07–6.85)
 
>60
1
1
BMI
 
<19
1.46 (0.83–2.59)
1.49 (0.65–3.43)
 
19–25
1
1
 
25–30
0.85 (0.66–1.10)
0.78 (0.51–1.20)
 
>30
0.78 (0.57–1.07)
1.05 (0.65–1.73)
Smoking status
 
Never smoked
1
1
 
Former smoker
0.85 (0.66–1.11)
1.02 (0.67–1.54)
 
Active smoker
0.76 (0.54–1.06)
1.66 (1.03–2.67)
Mean blood pressure (per mmHg)
1.01 (1.00–1.02)
1.01 (0.99–1.02)
Cardio-vascular history
0.63 (0.46–0.88)
0.81 (0.51–1.28)
ACR (mg/mmol)
 
<3
1
1
 
3–30
1.07 (0.82–1.40)
1.25 (0.76–2.08)
 
>30
0.80 (0.59–1.10)
1.13 (0.67–1.90)
Diabetes
 
0.86 (0.66–1.13)
1.56 (1.04–2.34)
Urine potassium
0.99 (0.99–1.00)
1.01 (1.00–1.01)
Serum albumin
 
≥35
1
1
 
<35
1.23 (0.87–1.74)
1.23 (0.76–1.98)
Serum potassium increasing drugsa
 
0.58 (0.44–0.78)
2.50 (1.17–5.35)
Serum potassium-lowering drugsb
1.70 (1.33–2.17)
1.01 (0.69–1.49)
a ACEi or ARBs or potassium-sparing diuretics b loop or thiazide diuretic, kayexalate or bicarbonates
BMI, body mass index, CVD, cardiovascular disease, mGFR, measured GFR, ACR, ratio of urinary albumin to creatinine
The analyses was adjusted for center
Originally Table 2 and its footnote were published as followed:
The analyses was adjusted for center
The correct version of Table 2 and its footnote is:
The analyses was adjusted for center
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Wagner et al. Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study (2017) 18:295 DOI 10.1186/s12882-017-0710-7 Wagner et al. Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study (2017) 18:295 DOI 10.1186/s12882-017-0710-7
Metadaten
Titel
Correction to: Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study
verfasst von
Sandra Wagner
Marie Metzger
Martin Flamant
Pascal Houillier
Jean-Philippe Haymann
François Vrtovsnik
Eric Thervet
Jean-Jacques Boffa
Ziad A. Massy
Bénédicte Stengel
Patrick Rossignol
for the NephroTest Study group
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
BMC Nephrology / Ausgabe 1/2017
Elektronische ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-017-0723-2

Weitere Artikel der Ausgabe 1/2017

BMC Nephrology 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.